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OBJECTIVES We sought to investigate baroreceptor regulation of sympathetic nerve activity and hemody-
namics after inhibition of nitric oxide (NO) synthesis.
BACKGROUND Both the sympathetic nervous system and endothelium-derived substances play essential roles
in cardiovascular homeostasis and diseases. Little is known about their interactions.
METHODS In healthy volunteers, we recorded muscle sympathetic nerve activity (MSA) with microneu-
rography and central hemodynamics measured at different levels of central venous pressure
induced by lower body negative pressure.
RESULTS After administration of the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA,
1 mg/kg/min), systolic blood pressure increased by 24 mm Hg (p 5 0.01) and diastolic blood
pressure by 12 mm Hg (p 5 0.009), while stroke volume index (measured by thermodilution)
fell from 53 to 38 mL/min/m2 (p , 0.002). Administration of L-NMMA prevented the
compensatory increase of heart rate, but not MSA, to orthostatic stress. The altered response
of heart rate was not due to higher blood pressure, because heart rate responses were not
altered during infusion of the alpha-1-adrenoceptor agonist phenylephrine (titrated to an
equal increase of systolic blood pressure). In the presence of equal systolic blood pressure and
central venous pressure, we found no difference in MSA during phenylephrine and
L-NMMA infusion.
CONCLUSIONS This study demonstrates a highly specific alteration of baroreceptor regulation of heart rate
but not muscle sympathetic activity after inhibition of NO synthesis in healthy volunteers.
This suggests an important role of NO in reflex-mediated heart rate regulation in humans. (J
Am Coll Cardiol 2000;36:213–8) © 2000 by the American College of Cardiology
The vascular endothelium synthesizes and releases nitric
oxide (NO) and plays a fundamental role in the basal and
dynamic regulation of the circulation (1–4). Apart from the
tone of peripheral resistance vessels, NO also regulates
myocardial contractility and is synthesized in neuronal cells
(5–8). However, little is known about the interactions of
NO and other cardiovascular regulating systems, especially
with the sympathetic nervous system. These interactions are
of particular interest in congestive heart failure, arterial
hypertension, atherosclerosis and septic shock, where sym-
pathetic nerves innervating and constricting blood vessels
act as important counterpart of the endothelium-derived
vasodilator NO (5,9–11).
Sympathetic activity is mainly regulated by baroreceptors
located in the cardiopulmonary and carotid vessel walls,
which centrally inhibit sympathetic outflow. These stretch-
activated mechanoreceptors not only regulate short-term
changes of blood pressure but also react to chronic elevation
of blood pressure by resetting sensitivity to a lower level
(12,13). In hypertension, altered baroreflex-mediated regu-
lation of muscle sympathetic nerve activity (MSA) has been
described (14). Similarly, in congestive heart failure, an
abnormal baroreflex contributes to sympathetic activation,
which is an unfavorable prognostic factor (15–19). Alter-
ations in endothelial function, with a resulting imbalance of
endothelium-derived relaxing and contracting factors, may
affect baroreceptor function because endothelial factors may
act on baroreceptor nerve endings in the vessel wall. Various
endogenous substances (e.g., NO, endothelin-1, prostacy-
clin, norepinephrine) have been shown to influence barore-
ceptor function in animals (12,20–24). It is not clear if these
mediators also affect human baroreceptor function.
The aim of our study was to investigate the effects of NO
synthase inhibition and alpha-1-adrenergic stimulation on
baroreceptor-mediated regulation of sympathetic nerve ac-
tivity, heart rate and hemodynamics in healthy humans.
METHODS
Subjects. Nine healthy normotensive volunteers (118 6
2/65 6 2 mm Hg, seven men and two women) with a mean
age of 26 years (range 21 to 35 years) participated in this study.
Right heart catheterization was performed in seven subjects
(five men and two women), of whom three (one man and two
women) were simultaneously studied by microneurography.
Microneurographic measurements of sympathetic activity and
noninvasive hemodynamic measurements were additionally
performed in two male volunteers (without right heart cathe-
terization). Each volunteer gave written, informed consent.
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Smokers and offspring of hypertensive parents were excluded
(25). None of the subjects was taking any medications.
Microneurographic measurements. Microneurography
was performed as described previously (25–27). Subjects
were studied in standardized fashion, that is, at 2 PM in a
quiet, temperature-controlled room, after micturition to
avoid any increase of sympathetic nerve activity through
bladder distension (10). Multifiber recordings of MSA were
obtained from the peroneal nerve. A reference electrode was
inserted subcutaneously 1 to 2 cm from the recording
electrode. Signals were amplified, filtered (700 to
2,000 Hz), integrated (time constant, 0.1 s) and digitized
using an analog-digital board (MIO-16L; National Instru-
ments, Austin, TX) and a modified commercial software
(LabView; National Instruments). Data recorded on a
computer (Macintosh Power PC 7100; Apple) were ana-
lyzed offline (MatLab; MathWorks, Natick, Massachu-
setts). The results were expressed as bursts per minute and
cumulative sum of the amplitude in volts per minute.
Lower body negative pressure. Lower body negative pres-
sure (LBNP) decreases central venous pressure by restricting
venous return of blood from the lower extremities to the
heart (28). We used an air-tight plexiglass chamber in
which the subjects were enclosed up to the waist. Negative
pressure was applied with a commercial vacuum cleaner (15
and 30 mm Hg, each for 2 min), monitored with a
manometer connected to the interior of the chamber.
Hemodynamic measurements. Cardiac output (average of
three measurements) was determined by thermodilution (Vig-
ilance Monitor Model VGS1; Baxter Healthcare Corporation,
Irvine, California) with a Swan-Ganz catheter (Model 746H-
8F; Baxter Healthcare Corporation) inserted through a sheath
introducer system (Cordis, Langenthal, Switzerland) in a
cubital vein and propagated to the pulmonary artery under
fluoroscopic guidance. Arterial blood pressure was measured
noninvasively (relative changes: Finapres; Ohmeda, Sweden;
absolute baseline values: Dinamap; Critikon, Tampa, Florida)
and a one-lead electrocardiogram was recorded and digitized
for computation of heart rate (29).
Experimental protocol. After recording stable baseline val-
ues for 15 min, phenylephrine was administered intravenously
through the distal lumen of the Swan-Ganz catheter (or a
peripheral intravenous line in three volunteers) at two dosages
(75 and 100 mg/min, each over 3 min at 0.75 and 1 ml/min).
Cardiac output was measured by thermodilution after each
dose of the drugs. During the last dose, LBNP was performed.
After reestablishing baseline conditions, NG-monomethyl-L-
arginine (L-NMMA) (Clinalfa, La¨ufelfingen, Switzerland)
was administered in two doses (0.3 and 1 mg/kg/min, each for
3 min at 1 to 3 ml/min) and cardiac output was determined
after each dose. Lower body negative pressure was performed
again. The drug infusion order was not alternated because of
the long elimination half life of L-NMMA.
Statistical analysis. Results are presented as means 6
SEM. Differences between drugs were evaluated using
paired Student t tests with Bonferroni adjusted p values for
multiple comparisons. The effects of LBNP were evaluated
by repeated-measures analysis of variance (StatView 4.5;
Abacus Concepts, Berkeley, California) (30). Statistical
significance was accepted at p , 0.05.
RESULTS
Hemodynamic effects. Changes in hemodynamic param-
eters and sympathetic nerve activity after administration of
drugs are shown in Table 1. L-NMMA and phenylephrine
caused dose-related increases in arterial blood pressure.
Abbreviations and Acronyms
LBNP 5 lower body negative pressure
L-NMMA 5 NG-monomethyl-L-arginine
MSA 5 muscle sympathetic nerve activity
NO 5 nitric oxide
Table 1. Hemodynamic and Sympathetic Nervous Effects of L-NMMA and Phenylephrine
Baseline
L-NMMA
(mg/kg/min)
Phenylephrine
(mg/min)
0.3 1.0 75 100
SBP 134 6 7 152 6 5 150 6 3* 155 6 7 153 6 8*
DBP 73 6 4 87 6 5 85 6 5† 88 6 6 90 6 5†
SVR 1,114 6 124 1,413 6 145* 1,973 6 203‡ 1,602 6 205† 1,743 6 209†
HR 67 6 4 70 6 6 63 6 6 57 6 5‡ 52 6 3‡
CI 3.5 6 0.3 3.1 6 0.2* 2.3 6 0.2§ 2.7 6 0.3† 2.6 6 0.2†
SVI 53 6 6 48 6 6 38 6 5† 51 6 8 51 6 4
CVP 4 6 0.7 3.6 6 0.4 4.3 6 0.05 6.3 6 0.5* 9.5 6 0.6†
B/min 23.1 6 3.5 14 6 4.5* 18.6 6 5.5 12.8 6 5.8 17.6 6 5.7
B/100 HB 35.6 6 5.8 21.3 6 7.6 32.8 6 10.8 21.7 6 9.4 33.8 6 10
ACS 100 53 6 27 67 6 21 26 6 16* 78 6 17
Values represent means 6 SEM (n 5 9 for noninvasive, n 5 7 for invasive hemodynamic, and n 5 5 for microneurographic
measurements). *p , 0.05, †p # 0.01, ‡p # 0.001, §p , 0.0001, for each data point compared with baseline values.
L-NMMA 5 NG-monomethyl-L-arginine; SBP 5 systolic blood pressure (mm Hg); DBP 5 diastolic blood pressure (mm
Hg); SVR 5 systemic vascular resistance (dyne/s/cm5); HR 5 heart rate (beats/min); CI 5 cardiac index (L/min/m2); SVI 5
stroke volume index (ml/min/m2); CVP 5 central venous pressure (mm Hg); B/min, sympathetic bursts per minute; B/100 HB
5 sympathetic bursts per 100 heartbeats; ACS 5 cumulative amplitude sum of sympathetic bursts (% change from baseline).
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After 0.3 mg/kg/min of L-NMMA, blood pressure increased
by 16.3% (p , 0.01); and by 18.6% after 1 mg/kg/min (p ,
0.01). Similar increases were achieved after 75 mg/min of
phenylephrine (118.6%, p , 0.05) and after 100 mg/min
(119.4%, p , 0.01; intergroup differences not significant).
Systemic vascular resistance changed accordingly by 126.8%
(p , 0.05) and 177.1% (p , 0.001) after L-NMMA and by
143.8% (p , 0.01) and 156.5% (p , 0.01) after phenyleph-
rine (intergroup differences not significant). At the higher
doses (1.0 mg/kg/min and 100 mg/min, respectively), increases
in arterial blood pressure were equal.
Heart rate was not affected by L-NMMA infusion
(14.5% and 26.0%, NS), in contrast to phenylephrine
where heart rate decreased (214.9% and 222.4%, p ,
0.001). Stroke volume index declined after the higher dose
of L-NMMA (228.3%, p 5 0.01) but not after phenyl-
ephrine. After phenylephrine, the decreased cardiac index
was related to a dose- and blood pressure-dependent fall in
heart rate. Central venous pressure was increased by phen-
ylephrine (143.6% and 1123%, p , 0.01), but was not
changed by L-NMMA.
LBNP. During administration of L-NMMA, heart rate,
but not MSA, failed to show a compensatory increase in
response to decreased central venous pressure induced by
LBNP (Fig. 1). This was in contrast to control conditions
and phenylephrine infusion.
Comparison of L-NMMA and phenylephrine. Muscle
sympathetic nerve activity was not significantly different
after L-NMMA and phenylephrine infusions, in the pres-
ence of equal systolic blood pressure and comparable central
venous pressure (Fig. 2). Stroke volume index was signifi-
cantly decreased by L-NMMA, and systemic peripheral
resistance was significantly higher during inhibition of NO
synthesis with L-NMMA than during infusion of phenyl-
ephrine (p , 0.05).
There were no adverse events during the study. Specifi-
cally, no clinical or electrocardiographic signs of ischemia
were observed.
DISCUSSION
This study shows that baroreflex regulation of heart rate but
not MSA in response to orthostatic stress is altered after
inhibition of NO synthesis in healthy subjects. Further-
more, inhibition of NO synthesis caused a decrease in
cardiac contractility.
Baroreceptor regulation in orthostatic stress. After in-
hibition of NO synthesis, heart rate failed to increase as a
counterregulatory mechanism to falling central venous pres-
sure induced by LBNP. Lower body negative pressure
simulates the cardiovascular effects of orthostatic stress or
hemorrhage by venous pooling of blood in the legs and
decreasing central venous pressure (31,32). Lower body
negative pressure ,20 mm Hg unloads the cardiopulmo-
nary mechanoreceptors; suction $20 mm Hg additionally
deactivates arterial baroreceptors and increases heart rate
(33). Both maneuvers result in an increase in sympathetic
nerve traffic to blood vessels of arm and leg muscles (28).
The observed altered baroreceptor response to orthostatic
stress is not due to an increased blood pressure level after
inhibition of NO synthesis, because heart rate increased
similarly during titrated infusions of phenylephrine. Addi-
tionally, it has been previously shown that different central
venous pressure levels do not influence sinus node responses
to arterial baroreceptor responses (34).
Potential explanations. The paradoxical bradycardia dur-
ing NO synthase inhibition in response to falling central
venous pressure and decreased stroke volume suggests the
requirement of some basal NO for baroreceptor regulation
of heart rate. This may take place at various anatomical
levels from alterations in: 1) baroreceptor sensitivity
(20,21,35–41); 2) central nervous coupling (8,35,42,43); 3)
pre- and postsynaptic autonomic nerve traffic (44,45); and
4) transmission of autonomic nerve activity to end-organ
cells (41,46–48). Our experiments do not allow us to
differentiate between these possibilities. It could be hypoth-
esized that NO is required as a parasympathetic messenger
for transmission of the effects of acetylcholine to cardiac
pacemaker cells. It was reported that alkyl esters of arginine
are muscarinic receptor antagonists; however, this is not the
case for L-NMMA (49). Because the response of peripheral
sympathetic nerve activity to orthostatic stress was not
Figure 1. Relative changes of central venous pressure (CVP), systolic blood
pressure, muscle sympathetic nerve activity (MSA, bursts per minute and
volts per minute) and heart rate during lower body negative pressure.
Central venous pressure similarly decreased in both drugs (*p , 0.05 vs.
baseline, intergroup differences NS). Also, there was no difference in
systolic blood pressure, which remained constant during lower body
negative pressure in both drugs. During infusion of L-NMMA
(1 mg/kg/min), heart rate failed to increase in response to decreased central
venous pressure. This was in contrast to phenylephrine (100 mg/min),
where heart rate increased (†p , 0.05 vs. phenylephrine; *p , 0.01 by
repeated-measures analysis of variance). Open circles 5 control; black
circles 5 L-NMMA; black boxes 5 phenylephrine.
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affected by L-NMMA, differential regulation of muscle and
cardiac sympathetic activity could be postulated (50,51). In
fact, a dissociation of MSA in arm and leg has been
described (52).
Endothelial and baroreceptor dysfunction. Our findings
partly reproduce the known alterations in baroreceptor
regulation in disease states with endothelial dysfunction.
Indeed, our results are in line with studies investigating
baroreflex control in hypertensive patients. Grassi et al. (14)
reported altered regulation of heart rate but not sympathetic
nerve activity in hypertension. In heart failure, abnormal
baroreceptor responses of heart rate and MSA to falling
central venous pressure, related in part to the severity of
hemodynamic abnormalities, have been demonstrated
(15,17,53,54). Alterations of baroreflex function may con-
tribute to elevated sympathetic nerve activity in heart failure
(18), which is an unfavorable prognostic factor
(17,19,54,55). Cardiopulmonary baroreflex control of sym-
pathetic nerve activity is also deranged in hypertension and
atherosclerosis (12,56,57), adding further evidence to the
concept of endothelium dependency of baroreflex.
Previous studies. Small doses of L-NMMA (50 mg/kg/
min) were reported to have stimulating effects on MSA,
whereas high doses decreased MSA (58). Combined infu-
sion of L-NMMA and nitroprusside increased MSA,
whereas mean arterial blood pressure was held constant.
Figure 2. Hemodynamics and muscle sympathetic nervous activity (MSA) at similar levels of systemic arterial (sBP) and central venous (CVP) blood
pressure after infusion of L-NMMA (1 mg/kg/min), and phenylephrine (PE, 100 mg/min) in combination with lower body negative pressure (LBNP
230 mm Hg). Stroke volume index (SVI) was significantly lower during L-NMMA infusion than during phenylephrine, whereas systemic vascular
resistance (SVR) was significantly higher. No significant difference in sympathetic nerve activity between L-NMMA and phenylephrine could be observed
(*p , 0.05).
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However, the effects of nitroprusside on central venous
pressure must not be neglected. Additionally, when com-
paring sympathetic outflow during L-NMMA and phenyl-
ephrine infusions, it must be taken into account that
phenylephrine increases central venous pressure (58,59).
Elevated central venous pressure activates cardiopulmonary
baroreceptors and therefore reduces sympathetic outflow.
We found no differences in MSA during L-NMMA and
phenylephrine when LBNP was used to achieve similar
central venous pressure.
Further effects of NO synthase inhibition. Our results
show that cardiac output is dependent on the availability of
some basal NO. This is in line with other studies in humans
(4). Constitutive and inducible forms of NO synthase are
present in human myocardium (60). Further, our findings
illustrate in vivo that venotonus is not determined by tonic
release of NO, in contrast to arterial tonus. In vitro
experiments comparing arterial and venous vessels showed
only weak endothelium-dependent relaxation in veins in
contrast to pronounced relaxation in arterial vessels (61).
Potential limitations. Unfortunately, it is not possible to
microneurographically measure cardiac sympathetic activity
or parasympathetic nerve traffic in humans. We used heart
rate as an end organ response as a marker of autonomic
nerve traffic to cardiac pacemaker cells.
Our findings are in contrast to reported experiments in
animals where NO synthase inhibition led to higher levels
of sympathetic activity (20,21,35,40), and had minimal (62)
or no effects on baroreflex regulation of heart rate (63).
Possibly, differences in the experimental setting (e.g., use of
anesthetics [64], isolation of the carotid sinus, species
differences) or other neurohumoral systems (e.g., the renin
angiotensin system [65], atrial natriuretic factor [66], argi-
nine vasopressin or nonadrenergic noncholinergic neuro-
transmitters [67]) prevent these effects to be revealed in
vivo.
Phenylephrine may exert effects on MSA and/or barore-
flex function by activation of alpha-1-adrenoceptors. In-
deed, norepinephrine effects on baroreceptor activity were
demonstrated in isolated carotid sinus preparations (22–24).
Alpha-1-adrenergic stimulation of phospholipase A2 leads
to the release of free arachidonate, which is then metabo-
lized to bioactive prostaglandins and leukotrienes. In addi-
tion, norepinephrine released from postsynaptic sympa-
thetic nerve endings acts as an autocrine negative feedback
loop on alpha-2-adrenoceptors.
Conclusions. This study demonstrates altered barorecep-
tor regulation of heart rate but not MSA after inhibition of
NO synthesis in healthy volunteers. These findings repro-
duce altered baroreflex regulation of heart rate in diseased
states with endothelial dysfunction, for example, arterial
hypertension and chronic heart failure. NO is required for
maintenance of cardiac output. Nitric oxide inhibition does
not lead to vasoconstriction of veins at rest, indicating a
small tonic effect of NO on venous vessels in vivo.
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